# Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

> **NCT00381888** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 44 (actual)

## Conditions studied

- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Sarcoma
- Thromboembolism
- Vaginal Cancer
- Vulvar Cancer

## Interventions

- **DRUG:** fondaparinux sodium

## Key facts

- **NCT ID:** NCT00381888
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381888, "Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00381888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*